Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?
{{output}}
Introduction: In the last years, there have been significant developments in the therapeutic armamentarium of metastatic castration-resistant prostate cancer (mCRPC). New evidence shows that the addition of bone-targeted agents (... ...
